EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 3.0

Effectiveness of Switching from Multiple-Inhaler to Once-Daily Single-Inhaler Triple Therapy in Patients with COPD in a Real-World Setting in Japan

Gema Requena iD, Lucinda J Camidge iD, Alexander Ford iD, Masao Yarita iD, Kenichi Hashimoto iD, Thomas Jennison iD, Olivia S Massey, Stephen G Noorduyn iD, Akiko Mizukami iD

International Journal of Chronic Obstructive Pulmonary Disease · 2025

DOI: 10.2147/copd.s478455 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von Gema Requena und 8 weiteren Autor:innen. Beteiligte Einrichtung: Value Evidence and Outcomes, R&D Global Medical, GSK, London, UK. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Bronchodilator Agents, Nebulizers and Vaporizers, Benzyl Alcohols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveBronchodilator AgentsNebulizers and VaporizersBenzyl AlcoholsQuinuclidinesChlorobenzenesAdrenergic beta-2 Receptor AgonistsLungMuscarinic AntagonistsHumansMaleFemaleRetrospective StudiesAgedJapanTreatment OutcomeAdministration, InhalationDrug CombinationsMiddle AgedTime FactorsDrug Administration ScheduleDisease ProgressionAged, 80 and overDatabases, FactualMedication Adherence

Stichwörter der Autor:innen

adherencechronic obstructive pulmonary disease exacerbationsclaims databasefluticasone furoate/umeclidinium/vilanterolmultiple-inhaler triple therapy

Substanzen

Drug CombinationsBronchodilator AgentsGSK573719Benzyl AlcoholsQuinuclidinesChlorobenzenesAdrenergic beta-2 Receptor AgonistsvilanterolMuscarinic Antagonists

Autor:innen und Institutionen

  • Value Evidence and Outcomes, R&D Global Medical, GSK, London, UK.
  • Real-World Evidence, Adelphi Real World, Bollington, UK.
  • Real World Data Analytics, Japan Development, GSK, Tokyo, Japan.
  • Value Evidence and Outcomes, Japan Medical Affairs, GSK, Tokyo, Japan.
  • Global Value Evidence and Outcomes, GSK, Mississauga, Ontario, Canada.
  • Department of Health Research Methods, Evidence, and Impact, McMaster University, Ontario, Canada.

ORCID-Profile: Gema Requena, Lucinda J Camidge, Alexander Ford, Masao Yarita, Kenichi Hashimoto, Thomas Jennison, Stephen G Noorduyn, Akiko Mizukami

Zitieren

APA

Requena, G., Camidge, L. J., Ford, A., Yarita, M., Hashimoto, K., Jennison, T., Massey, O. S., Noorduyn, S. G., & Mizukami, A. (2025). Effectiveness of Switching from Multiple-Inhaler to Once-Daily Single-Inhaler Triple Therapy in Patients with COPD in a Real-World Setting in Japan. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s478455

Vancouver

Requena G, Camidge LJ, Ford A, Yarita M, Hashimoto K, Jennison T, et al. Effectiveness of Switching from Multiple-Inhaler to Once-Daily Single-Inhaler Triple Therapy in Patients with COPD in a Real-World Setting in Japan. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s478455

BibTeX
@article{Requena2025,
  author = {Requena, Gema and Camidge, Lucinda J and Ford, Alexander and Yarita, Masao and Hashimoto, Kenichi and Jennison, Thomas and Massey, Olivia S and Noorduyn, Stephen G and Mizukami, Akiko},
  title = {Effectiveness of Switching from Multiple-Inhaler to Once-Daily Single-Inhaler Triple Therapy in Patients with COPD in a Real-World Setting in Japan},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  doi = {10.2147/copd.s478455}
}
Kostenlos starten →